iRadimed Q2 Adj. EPS $0.46 Beats $0.42 Estimate, Sales $20.466M Beat $20.350M Estimate
Share
Why It Matters
iRadimed made a little more money than people expected in the last three months, which means the company is doing well. When a company beats what people predicted, it's a good sign they're running their business smartly.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.